Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
$9.85
+1.1%
$8.84
$4.64
$58.90
$114.83M3.0897,333 shs153,927 shs
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$0.46
+40.4%
$0.36
$0.25
$0.48
$39.14M1.08913,992 shs214,616 shs
Scilex Holding Company stock logo
SCLX
Scilex
$18.86
+1.2%
$12.72
$3.60
$41.30
$123.53M1.34244,008 shs152,711 shs
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
$1.18
+9.3%
$0.84
$0.36
$4.01
$184.16M3.073.96 million shs2.14 million shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
+3.95%-2.89%+4.62%+14.99%-84.08%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
+3.50%+14.73%+29.45%+42.31%+23.47%
Scilex Holding Company stock logo
SCLX
Scilex
+4.95%+3.44%+39.00%+167.43%-53.69%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-4.42%0.00%+61.05%+105.05%-59.70%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.9062 of 5 stars
3.62.00.04.72.21.70.0
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
1.6573 of 5 stars
3.50.00.00.01.41.70.0
Scilex Holding Company stock logo
SCLX
Scilex
2.6198 of 5 stars
3.32.00.00.03.71.70.6
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
2.9384 of 5 stars
3.51.00.00.02.54.20.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.10
Buy$49.00397.46% Upside
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.00
Buy$3.88746.07% Upside
Scilex Holding Company stock logo
SCLX
Scilex
2.50
Moderate Buy$455.002,312.51% Upside
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
3.00
Buy$6.25429.66% Upside

Current Analyst Ratings Breakdown

Latest IGC, TNYA, CRBP, and SCLX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/2/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/27/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00
8/7/2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$9.00
8/6/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$56.00 ➝ $53.00
7/30/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy$28.00
7/12/2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/A$9.06 per shareN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
$1.33M31.34N/AN/A$0.08 per share5.73
Scilex Holding Company stock logo
SCLX
Scilex
$56.59M2.32N/AN/A($35.80) per share-0.53
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/A$0.61 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$40.21M-$4.76N/AN/AN/AN/A-43.65%-39.62%11/6/2025 (Estimated)
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
-$13M-$0.07N/AN/AN/A-714.16%-122.44%-88.40%N/A
Scilex Holding Company stock logo
SCLX
Scilex
-$72.81M-$29.02N/AN/AN/A-179.12%N/A-109.95%11/12/2025 (Estimated)
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$111.13M-$0.96N/AN/AN/AN/A-93.83%-75.66%11/5/2025 (Estimated)

Latest IGC, TNYA, CRBP, and SCLX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Scilex Holding Company stock logo
SCLX
Scilex
-$4.55-$7.42-$2.87-$7.42$26.25 million$9.90 million
8/6/2025Q2 2025
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
-$0.20-$0.14+$0.06-$0.14N/AN/A
8/5/2025Q2 2025
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
-$1.55-$1.44+$0.11-$1.44N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/AN/AN/AN/AN/A
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
N/AN/AN/AN/AN/A
Scilex Holding Company stock logo
SCLX
Scilex
N/AN/AN/AN/AN/A
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
N/A
9.21
9.21
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
0.02
1.15
0.98
Scilex Holding Company stock logo
SCLX
Scilex
N/A
0.11
0.10
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
N/A
6.00
6.00

Institutional Ownership

CompanyInstitutional Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
64.64%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
3.87%
Scilex Holding Company stock logo
SCLX
Scilex
69.67%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
90.54%

Insider Ownership

CompanyInsider Ownership
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
3.60%
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
23.66%
Scilex Holding Company stock logo
SCLX
Scilex
7.94%
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
48.65%
CompanyEmployeesShares OutstandingFree FloatOptionable
Corbus Pharmaceuticals Holdings, Inc. stock logo
CRBP
Corbus Pharmaceuticals
4012.26 million11.77 millionOptionable
IGC Pharma, Inc. stock logo
IGC
IGC Pharma
6190.81 million54.60 millionN/A
Scilex Holding Company stock logo
SCLX
Scilex
806.96 million6.40 millionOptionable
Tenaya Therapeutics, Inc. stock logo
TNYA
Tenaya Therapeutics
110162.98 million83.69 millionOptionable

Recent News About These Companies

Tenaya (TNYA) Q2 Loss Narrows 59%

New MarketBeat Followers Over Time

Media Sentiment Over Time

Corbus Pharmaceuticals stock logo

Corbus Pharmaceuticals NASDAQ:CRBP

$9.85 +0.11 (+1.13%)
Closing price 04:00 PM Eastern
Extended Trading
$9.71 -0.14 (-1.42%)
As of 07:12 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.

IGC Pharma stock logo

IGC Pharma NYSEMKT:IGC

$0.46 +0.13 (+40.45%)
Closing price 03:58 PM Eastern
Extended Trading
$0.46 0.00 (-0.66%)
As of 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IGC Pharma, Inc., a clinical stage pharmaceutical company, engages in developing treatments for Alzheimer's disease. The company's lead product is IGC-AD1, which is in a Phase 2B clinical trial as a treatment for agitation in dementia due to Alzheimer's; and TGR-63, IGC-1C, IGC-M3, and LMP in pre-clinical development. The company was formerly known as India Globalization Capital, Inc. and changed its name to IGC Pharma, Inc. in March 2023. The company was incorporated in 2005 and is headquartered in Potomac, Maryland.

Scilex stock logo

Scilex NASDAQ:SCLX

$18.86 +0.22 (+1.18%)
Closing price 04:00 PM Eastern
Extended Trading
$18.77 -0.09 (-0.45%)
As of 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Scilex Holding Company focuses on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Its commercial products include ZTlido (lidocaine topical system) 1.8% (ZTlido), a prescription lidocaine topical product for the relief of neuropathic pain associated with postherpetic neuralgia (PHN), which is a form of post-shingles nerve pain; ELYXYB, a ready-to-use oral solution for the acute treatment of migraine with or without aura in adults; and GLOPERBA, a liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. The company is also developing three product candidates, including SP-102 (10 mg dexamethasone sodium phosphate viscous gel) (SEMDEXA), a novel viscous gel formulation of a used corticosteroid for epidural injections, which has completed a Phase 3 study to treat lumbosacral radicular pain or sciatica; SP-103 (lidocaine topical system) 5.4% (SP-103), a formulation of ZTlido for the treatment of chronic neck pain and low back pain (LBP) that has completed a Phase 2 trial; and SP-104 (4.5 mg low-dose naltrexone hydrochloride delayed-release capsules) (SP-104), a novel low-dose delayed-release naltrexone hydrochloride, which has completed Phase 1 trials for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California.

Tenaya Therapeutics stock logo

Tenaya Therapeutics NASDAQ:TNYA

$1.18 +0.10 (+9.26%)
Closing price 04:00 PM Eastern
Extended Trading
$1.18 0.00 (-0.42%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.